2nd Quarter - Report

FIERCE GOVERNMENT RELATIONS for ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, S.1041 - Affordable Prescriptions for Patients Act, S.43 - Skinny Labels - Big Savings Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1954- Biosimilar Red Tape Reduction Act, S.1414 - Expected Access to Biosimilars Act, Access to Biosimilars, Generic Manufacturing Marketplace Issues

LobbyistCovered position, as disclosed
WILLIAM KIRK BLALOCK —
KIRSTEN CHADWICK —
MICHAEL CHAPPELL —
PATRICK CLIFTON New Special Asst. to the President for Operations, Executive Office of the President, President Donald J. Trump (17-19).
KATE HULL —
WILLIAM PIPER —
TYLER STEPHENS —
ERIC ZULKOSKY —

Contacted: Food & Drug Administration (FDA); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 43 (119th), S. 1302 (119th), S. 1041 (119th), S. 1414 (119th), S. 1954 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.